La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Artiva Biotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Artiva Biotherapeutics..

Artiva Biotherapeutics (NASDAQ:ARTV) Azioni, Catena delle Opzioni

ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics Inc

News

Press Releases

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Management

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Health Care

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Earnings

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

ARTV

CTNM

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Atossa Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Coya Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immix Biopharma

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Opus Genetics

MDxHealth

Macrogenics

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

Oncolytics Biotech

Ovid Therapeutics

Pelthos Therapeutics

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

Surrozen

Tevogen Bio Holdings

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Artiva Biotherapeutics

Artiva Biotherapeutics (ARTV) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO